| Name | Title | Contact Details |
|---|
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
Grabber Performance Group is a Wyoming, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orthopaedic Innovations Inc is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PIXI is a Culver City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ozone House-one is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.